RxDoctor Payments Data

Ivy Thompson

Nurse Practitioner · Milford, DENPI 1164079828

Payments from drug & device makers

$1,686in general payments, 2019–2025

Across 73 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$646
  • Novo Nordisk$230
  • Exact Sciences$145
  • Pfizer$102
  • Corcept Therapeutics$102
  • Bayer$85
  • plus $376 from 8 others

What the payments were for

  • Food & beverage$1,686100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,686 in reported general payments places this provider in the 80th percentile of 487 nurse practitioner providers in Delaware.

See all nurse practitioner providers in Delaware

Medicare billing

Part B allowed, 2024
$1,950
Medicare patients
15
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$83,789
JardianceEmpagliflozin20$26,452
EliquisApixaban20$23,778
MounjaroTirzepatide12$18,086
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$14,248
FarxigaDapagliflozin Propanediol11$12,590
Albuterol Sulfate HfaAlbuterol Sulfate138$4,733
Ezetimibe52$2,617
Omeprazole161$2,541
Gabapentin99$2,518
Atorvastatin Calcium243$2,372
Metoprolol Succinate86$1,341
Amlodipine Besylate184$1,303
Levothyroxine Sodium102$1,021
Rosuvastatin Calcium69$1,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$230$83,78963 claims
Boehringer IngelheimJardiance$35$26,45220 claims
PfizerEliquis$102$23,77820 claims
Lilly USA, LLCMounjaro$18$18,08612 claims
GSKTrelegy Ellipta$39$14,24813 claims
AstraZenecaFarxiga$646$12,59011 claims
AbbVieSynthroid$72$82122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 487 nurse practitioner providers in Delaware.

Other nurse practitioner in Milford

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →